ID   LECG_BOTJR              Reviewed;         159 AA.
AC   P83519; Q6TRS6; Q7T228;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   26-JUN-2013, sequence version 2.
DT   03-AUG-2022, entry version 72.
DE   RecName: Full=C-type lectin BJcuL {ECO:0000303|PubMed:11478954, ECO:0000303|PubMed:28003128};
DE            Short=CTL;
DE   AltName: Full=Galactose-specific lectin;
DE   AltName: Full=Snake venom galactoside-binding lectin {ECO:0000303|PubMed:28003128};
DE            Short=SVgalL {ECO:0000303|PubMed:28003128};
DE   Flags: Precursor;
OS   Bothrops jararacussu (Jararacussu).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Lepidosauria; Squamata; Bifurcata; Unidentata; Episquamata; Toxicofera;
OC   Serpentes; Colubroidea; Viperidae; Crotalinae; Bothrops.
OX   NCBI_TaxID=8726;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Venom gland;
RX   PubMed=15135412; DOI=10.1016/j.pep.2004.02.012;
RA   Kassab B.H., de Carvalho D.D., Oliveira M.A., Baptista G.R., Pereira G.A.,
RA   Novello J.C.;
RT   "Cloning, expression, and structural analysis of recombinant BJcuL, a c-
RT   type lectin from the Bothrops jararacussu snake venom.";
RL   Protein Expr. Purif. 35:344-352(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-159.
RC   TISSUE=Venom gland;
RX   PubMed=15134836; DOI=10.1016/j.biochi.2004.02.002;
RA   Kashima S., Roberto P.G., Soares A.M., Astolfi-Filho S., Pereira J.O.,
RA   Giuliati S., Faria M. Jr., Xavier M.A.S., Fontes M.R.M., Giglio J.R.,
RA   Franca S.C.;
RT   "Analysis of Bothrops jararacussu venomous gland transcriptome focusing on
RT   structural and functional aspects: I -- gene expression profile of highly
RT   expressed phospholipases A2.";
RL   Biochimie 86:211-219(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 25-159.
RC   TISSUE=Venom;
RX   PubMed=11902666; DOI=10.1023/a:1014131115951;
RA   de Carvalho D.D., Marangoni S., Novello J.C.;
RT   "Primary structure characterization of Bothrops jararacussu snake venom
RT   lectin.";
RL   J. Protein Chem. 21:43-50(2002).
RN   [4]
RP   PROTEIN SEQUENCE OF 25-44.
RC   TISSUE=Venom;
RX   PubMed=15994137; DOI=10.1016/j.jchromb.2005.04.018;
RA   De-Simone S.G., Correa-Netto C., Antunes O.A., De-Alencastro R.B.,
RA   Silva F.P. Jr.;
RT   "Biochemical and molecular modeling analysis of the ability of two p-
RT   aminobenzamidine-based sorbents to selectively purify serine proteases
RT   (fibrinogenases) from snake venoms.";
RL   J. Chromatogr. B 822:1-9(2005).
RN   [5]
RP   PROTEIN SEQUENCE OF 25-32, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND
RP   ACTIVITY REGULATION.
RC   TISSUE=Venom;
RA   de Carvalho D.D., Marangoni S., Oliveira B., Novello J.C.;
RT   "Isolation and characterization of a new lectin from the venom of the snake
RT   Bothrops jararacussu.";
RL   Biochem. Mol. Biol. Int. 44:933-938(1998).
RN   [6]
RP   FUNCTION.
RX   PubMed=10628348;
RA   Pereira-Bittencourt M., de Carvalho D.D., Gagliardi A.R., Collins D.C.;
RT   "The effect of a lectin from the venom of the snake, Bothrops jararacussu,
RT   on tumor cell proliferation.";
RL   Anticancer Res. 19:4023-4025(1999).
RN   [7]
RP   FUNCTION.
RX   PubMed=11478954; DOI=10.1016/s0041-0101(01)00106-4;
RA   de Carvalho D.D., Schmitmeier S., Novello J.C., Markland F.S.;
RT   "Effect of BJcuL (a lectin from the venom of the snake Bothrops
RT   jararacussu) on adhesion and growth of tumor and endothelial cells.";
RL   Toxicon 39:1471-1476(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=21266049; DOI=10.1186/1471-2172-12-10;
RA   Elifio-Esposito S., Tomazeli L., Schwartz C., Gimenez A.P., Fugii G.M.,
RA   Fernandes L.C., Zishler L.F., Stuelp-Campelo P.M., Moreno A.N.;
RT   "Human neutrophil migration and activation by BJcuL, a galactose binding
RT   lectin purified from Bothrops jararacussu venom.";
RL   BMC Immunol. 12:10-10(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND BIOTECHNOLOGY.
RC   TISSUE=Venom;
RX   PubMed=25811661; DOI=10.1371/journal.pone.0120514;
RA   Klein R.C., Fabres-Klein M.H., de Oliveira L.L., Feio R.N., Malouin F.,
RA   Ribon A.O.;
RT   "A C-type lectin from Bothrops jararacussu venom disrupts Staphylococcal
RT   biofilms.";
RL   PLoS ONE 10:E0120514-E0120514(2015).
RN   [10]
RP   FUNCTION, BIOASSAY, AND ACTIVITY REGULATION.
RC   TISSUE=Venom;
RX   PubMed=16309723; DOI=10.1016/j.toxicon.2005.08.012;
RA   Panunto P.C., da Silva M.A., Linardi A., Buzin M.P., Melo S.E., Mello S.M.,
RA   Prado-Franceschi J., Hyslop S.;
RT   "Biological activities of a lectin from Bothrops jararacussu snake venom.";
RL   Toxicon 47:21-31(2006).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 26-159 (HOMODECAMER) IN COMPLEX
RP   WITH AMINOGLYCOSIDE ANTIBIOTICS, FUNCTION, METAL-BINDING SITES, SUBUNIT,
RP   DISULFIDE BOND, AND ACTIVITY REGULATION.
RC   TISSUE=Venom;
RX   PubMed=28003128; DOI=10.1016/j.toxicon.2016.12.007;
RA   Sartim M.A., Pinheiro M.P., de Padua R.A.P., Sampaio S.V., Nonato M.C.;
RT   "Structural and binding studies of a C-type galactose-binding lectin from
RT   Bothrops jararacussu snake venom.";
RL   Toxicon 126:59-69(2017).
CC   -!- FUNCTION: Galactose-binding lectin which recognizes specific
CC       carbohydrate structures and agglutinates a variety of animal cells by
CC       binding to cell-surface glycoproteins and glycolipids. Calcium-
CC       dependent lectin. Also binds lactose and raffinose (PubMed:28003128).
CC       Shows high hemagglutinating activity on mammalian erythrocytes (Ref.5,
CC       PubMed:16309723). It also involved in immunological functions, since it
CC       is able of inducing potent neutrophil activation (PubMed:21266049,
CC       PubMed:16309723). In vivo, it causes edema and increases vascular
CC       permeability after injection into mouse hind paws (10-100 ug/paw). In
CC       anesthetized rats, it decreases the blood pressure by approximately
CC       15%, with a rapid return to the resting level (PubMed:16309723). Is an
CC       effective inhibitor of cell growth in some cancer cell lines,
CC       especially against renal and pancreatic cancer cell lines, human breast
CC       and ovarian carcinoma, glioblastoma and a bovine brain microvascular
CC       endothelial cell line (PubMed:10628348, PubMed:11478954).
CC       {ECO:0000269|PubMed:10628348, ECO:0000269|PubMed:11478954,
CC       ECO:0000269|PubMed:16309723, ECO:0000269|Ref.5}.
CC   -!- ACTIVITY REGULATION: Hemagglutination activity is inhibited by lactose
CC       (MIC=2.5 mM), galactose (MIC=10 mM), and raffinose (Ref.5,
CC       PubMed:16309723, PubMed:28003128). Is very weakly or not inhibited by
CC       gentamicin, kanamycin, glucose and sucrose (PubMed:16309723,
CC       PubMed:28003128). {ECO:0000269|PubMed:16309723,
CC       ECO:0000269|PubMed:28003128, ECO:0000269|Ref.5}.
CC   -!- SUBUNIT: Homodecamer of disulfide-linked dimers arranged in two 5-fold
CC       symmetric pentamers (Ref.5, PubMed:28003128). Binds the gentamicin
CC       group of aminoglycoside antibiotics at the dimeric interface near the
CC       intermolecular disulfide bond (PubMed:28003128).
CC       {ECO:0000269|PubMed:28003128, ECO:0000305|Ref.5}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|Ref.5}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland. {ECO:0000305|Ref.5}.
CC   -!- BIOTECHNOLOGY: Can be used in the treatment of bovine mastitis, since
CC       it is able to both inhibit bacterial biofilm growth, and disrupt
CC       existing biofilm, without affecting bacterial cell viability.
CC       {ECO:0000305|PubMed:25811661}.
CC   -!- MISCELLANEOUS: The lectin (up to 200 microg/ml) does not aggregate
CC       human platelet-rich plasma (PRP) or washed platelets (WP), nor does it
CC       alter the aggregation induced by ADP in PRP or by thrombin in WP.
CC       {ECO:0000305|PubMed:16309723}.
CC   -!- SIMILARITY: Belongs to the true venom lectin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP42417.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY388642; AAQ92957.1; -; mRNA.
DR   EMBL; AY251283; AAP42417.1; ALT_INIT; mRNA.
DR   PDB; 5F2Q; X-ray; 2.95 A; A/B/C/D/E/F/G/H/I/J=25-159.
DR   PDBsum; 5F2Q; -.
DR   AlphaFoldDB; P83519; -.
DR   SMR; P83519; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030308; P:negative regulation of cell growth; TAS:UniProtKB.
DR   Gene3D; 3.10.100.10; -; 1.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR016187; CTDL_fold.
DR   Pfam; PF00059; Lectin_C; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SUPFAM; SSF56436; SSF56436; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Direct protein sequencing; Disulfide bond;
KW   Hemagglutinin; Lectin; Metal-binding; Secreted; Signal.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:11902666,
FT                   ECO:0000269|PubMed:15994137, ECO:0000269|Ref.5"
FT   CHAIN           25..159
FT                   /note="C-type lectin BJcuL"
FT                   /evidence="ECO:0000269|PubMed:11902666"
FT                   /id="PRO_0000046643"
FT   DOMAIN          34..156
FT                   /note="C-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   MOTIF           120..122
FT                   /note="Galactose-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P21963"
FT   BINDING         120
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   BINDING         122
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   BINDING         128
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   BINDING         143
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   BINDING         144
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   SITE            103
FT                   /note="Binds aminoglycoside antibiotics (subunit E')"
FT                   /evidence="ECO:0000269|PubMed:28003128"
FT   SITE            104
FT                   /note="Binds aminoglycoside antibiotics (subunit A and E')"
FT                   /evidence="ECO:0000269|PubMed:28003128"
FT   SITE            105
FT                   /note="Binds aminoglycoside antibiotics (subunit A)"
FT                   /evidence="ECO:0000269|PubMed:28003128"
FT   SITE            109
FT                   /note="Binds aminoglycoside antibiotics (subunit A)"
FT                   /evidence="ECO:0000269|PubMed:28003128"
FT   SITE            111
FT                   /note="Binds aminoglycoside antibiotics (subunit A and E')"
FT                   /evidence="ECO:0000269|PubMed:28003128"
FT   DISULFID        27..38
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   DISULFID        55..155
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   DISULFID        62..157
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   DISULFID        110
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:28003128"
FT   DISULFID        130..147
FT                   /evidence="ECO:0000269|PubMed:28003128,
FT                   ECO:0007744|PDB:5F2Q"
FT   CONFLICT        43
FT                   /note="N -> D (in Ref. 3; AA sequence and 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        88
FT                   /note="S -> A (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        95
FT                   /note="C -> Q (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        136
FT                   /note="N -> L (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        143
FT                   /note="N -> E (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        156
FT                   /note="Q -> H (in Ref. 1; AAQ92957)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        159
FT                   /note="F -> LGTSSKG (in Ref. 1; AAQ92957)"
FT                   /evidence="ECO:0000305"
FT   STRAND          31..34
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          37..47
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   HELIX           48..58
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          59..64
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   HELIX           72..83
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          90..101
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   HELIX           124..126
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          128..133
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   HELIX           135..137
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          141..146
FT                   /evidence="ECO:0007829|PDB:5F2Q"
FT   STRAND          149..157
FT                   /evidence="ECO:0007829|PDB:5F2Q"
SQ   SEQUENCE   159 AA;  18653 MW;  CA54B549F208D1D5 CRC64;
     MGRFLFVASS ACWFVFLSLS GAKGNNCPQD WLPMNGLCYK IFNELKAWKD AEMFCRKYKP
     GCHLASIHLY GESPEIAEYI SDYHKGQSEV WIGLCDKKKD FSWEWTDRSC TDYLSWDKNQ
     PDHYQNKEFC VELVSNTGYR LWNDQVCESK NAFLCQCKF
//
